About - Scailyte

WARNING: Beware of Scam Using Our Company Name for Fake Job Interviews

Experts in single-cell science, -omics analytics, and AI.

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex molecular and cellular patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (scRNA-seq, CITE-seq, CyTOF, TCR-/BCR-seq, etc.) with clinical endpoints, such as disease progression, severity, treatment response and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. Our discoveries elucidate drug MoA and inform on the risk benefit ratio.

The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in various clinical projects in immunology and oncology.

To save lives by enabling precision medicine.

Dr. Peter Nestorov

Founder & Chief Executive Officer

Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.

Tim Foley

Chief Business Officer

Tim, with over 20 years of experience in business development and deal-making primarily at Takeda and Astellas, now focuses on precision medicine, driving partnerships and funding in healthtech. Holding an MBA from DePaul’s Kellstadt Graduate School of Business, his expertise and dynamic approach are set to expand our biomarker discovery platform into the American market. Tim joined Scailyte as a Chief Business Officer in 2024.

Dr. Sarah Carl

Director Data Science

Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and now serves as Director of Data Science.

Anna Dimitrova, ACCA

Chief Financial Officer

Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.

Dennis Göhlsdorf

Machine Learning Engineer

Dennis is a multi-disciplinary professional with degrees in both Biochemistry and Computer Science obtained from the University of Tuebingen. He earned his PhD at the Institute of Neuroinformatics at ETH Zurich / University of Zurich. From 2013 until 2016, he worked as a Software Engineer at Google Germany, focusing on Image processing algorithms. He co-founded Scailyte in 2016 and is currently working in the data science team.

Our team

Jean-Pierre Rosat

General Partner & Founder at 4FOX Ventures & Scailyte Chair of the Board of Directors

Jean-Pierre Rosat, Founder and General Partner at 4FOX Ventures, has over two decades of management experience, notably in spearheading start-ups and securing significant funding. He holds advanced degrees in biology and immunology from the University of Lausanne, complemented by a post-doc at Harvard Medical School.

Jan Lichtenberg

Chief Executive Officer InSphero & Scailyte Board of Directors

Jan Lichtenberg is Chief Executive Officer and Co-founder of InSphero, the world-leading biotech specialising in 3D cell-culture technologies for discovery and safety.

Darrin Crisitello

Chief Commercial Office at Quanterix & Scailyte Board of Directors

Darrin joined Quanterix in 2021 as Chief Commercial Officer, bringing over 20 years of experience in team leadership and business development within biotechnology sectors. He holds a BS in biology and chemistry from Moravian College and an MBA from the University of Massachusetts.

Peter Ibbotson

Partner at Swisscom Ventures & Scailyte Board of Directors

Peter Ibbotson is Investor Relations Partner at Swisscom Ventures. He joined Swisscom Ventures in 2017 and is responsible for investor relations and fund administration.

Dr. Corinne Solier

Scailyte Board of Directors Advisor

Corinne obtained a Masters in Engineering Sciences in Biotechnology and a PhD in Immunology from Université Paul Sabatier in Toulouse, France. She pursued postdoctoral studies at the City of Hope National Medical Center in the U.S.A. in the field of nuclear receptor biochemistry before joining Roche Pharmaceuticals. There, she held various positions in early research and development, intersecting with translational biomarker science, cutting-edge “omics” technologies and innovation. At Scailyte, she transitioned from an executive role as SVP of Corporate and Technology Development to a strategic role as an Advisor of the Board of Directors.

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis

Manfred holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich.

Vijay Tiwari

Professor in Genomics at QUB & Scailyte Executive Advisor

Vijay is a Professor in Genomics at QUB, working on achieving an integrated molecular and systems-level understanding of cancer and neurological disorders.

Prof. Laura Chow

Affiliate Professor Oncology at UoT, Medical Oncologist & Scailyte Advisor

Laura Chow, a renowned medical oncology physician and professor, has significantly influenced the standards of clinical care, research, and education in various cancers over the last 20 years. She has held prestigious roles at the University of Texas at Austin and MD Anderson, spearheading clinical trials and training programs while contributing to international and national guidelines on cancer care.

Prof. Dr. Jakob Kather

Professor in Digital Health at TUD & Scailyte Advisor

Jakob serves as a full professor at the Else Kroener Fresenius Center for Digital Health, Technical University Dresden, and as a senior physician in medical oncology at University Hospital Dresden. His research, supported by numerous grants, focuses on developing AI applications for precision oncology.

Virginia Savova, PhD

Strategic & Scientific Advisor

Dr. Savova has expertise in computational biology, immunology, and cancer research, having developed single-cell technologies and AI applications at Harvard Medical School and Dana Farber Cancer Institute. Previously, as Senior Director at Sanofi, she focused on single-cell applications for drug development.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

To achieve our mission, we are looking for smart, passionate and dedicated individuals who share our values by dreaming big, to join our growing, energetic and fun team. We offer flexible working schedules and location.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Global Entrepreneurship Week Basel

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Recent News

03 /04

Global Entrepreneurship Week Basel

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Our vision

Enabling precision medicine to save millions of lives!

Who We Are

Mission

Our mission is to advance precision medicine with single-cell technologies, artificial intelligence, and multiomics analysis.

Our Values

Vision